STOCK TITAN

Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Corbus Pharmaceuticals Holdings (CRBP) presented Phase 1b CANYON-1 obesity data showing 5% mean weight loss with CRB-913 at 12 weeks. The placebo-controlled study enrolled 254 non-diabetic adults with obesity. Mean weight loss was 2.8%, 3.3% and 5.0% at 20 mg, 40 mg and 60 mg, respectively, versus 0.0% with placebo; all comparisons had p<0.0001. Waist circumference and body mass index also declined, with no weight-loss plateau observed.

Safety results included no serious treatment-related adverse events and no serious or severe psychiatric events. However, four participants had serious treatment-emergent events, meaning events arising during treatment regardless of cause. Adverse-event discontinuations were 8.3% across all cohorts, including placebo, and 12.9% at 60 mg. Corbus plans FDA discussions on the data and development plans and is evaluating potential combinations with GLP-1 therapies.

Loading...
Loading translation...
12 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 15 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointWeek-12 mean weight loss was 2.8%, 3.3% and 5.0% at 20/40/60 mg versus 0.0% with placebo; all p<0.0001.
  • Minor pointNo weight-loss plateau was observed at any CRB-913 dose during the study.
  • Minor pointWaist circumference changed by -3.03/-3.04/-3.94 cm at 20/40/60 mg versus -0.84 cm with placebo.
  • Minor pointBody mass index changed by -2.81%/-3.34%/-4.99% at 20/40/60 mg versus -0.06% with placebo.
  • Minor pointAll 60 mg study completers lost weight; 44.4% lost at least 5.0% from baseline.
7 minor points
  • Minor pointWeight loss above 7.5% occurred in 6.7% of 60 mg study completers; the highest recorded loss was 13.4%.
  • Minor pointNo serious treatment-related adverse events occurred in any cohort.
  • Minor pointNo serious or severe psychiatric events or suicidality were reported; all psychiatric adverse events resolved.
  • Minor pointGastrointestinal events were all mild or moderate, with no serious or severe cases.
  • Minor pointVomiting, nausea and constipation were less frequent and milder than published oral GLP-1 results, Corbus said.
  • Minor point. Forward-looking: it has not happened yet and may not happen.FDA discussions on CRB-913 data and development plans are planned by Corbus.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Combination development with GLP-1 therapies is being evaluated by Corbus.

Negative

  • Moderate pointAdverse-event discontinuations were 3.1%/13.1%/12.9% at 20/40/60 mg versus 4.5% with placebo; overall, 8.3%.
  • Minor pointTreatment-emergent adverse events affected 60.0%/73.8%/72.6% at 20/40/60 mg versus 42.4% with placebo.
  • Minor pointSerious treatment-emergent events affected 2/1/1 participants at 20/40/60 mg versus none with placebo.
  • Minor pointSevere treatment-emergent events affected 3/2/1 participants at 20/40/60 mg versus none with placebo.
  • Minor pointTreatment-related adverse events affected 41.5%/55.7%/53.2% at 20/40/60 mg versus 21.2% with placebo.
10 minor points
  • Minor pointOne severe treatment-related event occurred in the 40 mg cohort, affecting 1.6% of participants.
  • Minor pointAll-cause treatment discontinuations were 15.4%/26.2%/25.8% at 20/40/60 mg versus 18.2% with placebo.
  • Minor pointModerate depressive symptoms occurred in one 60 mg participant, or 1.6%, versus none in other cohorts.
  • Minor pointAnxiety affected 3.1%/8.2%/4.8% at 20/40/60 mg versus 4.5% with placebo.
  • Minor pointMild irritability affected 15 CRB-913 participants (8%); it resolved spontaneously without affecting daily function.
  • Minor pointNausea affected 15.4%/26.2%/22.6% at 20/40/60 mg versus 4.5% with placebo.
  • Minor pointDiarrhea affected 21.5%/26.2%/22.6% at 20/40/60 mg versus 3.0% with placebo.
  • Minor pointVomiting affected 4.6%/8.2%/1.6% at 20/40/60 mg versus none with placebo.
  • Minor pointConstipation affected 4.6%/1.6%/4.8% at 20/40/60 mg versus 3.0% with placebo.
  • Minor pointGastrointestinal adverse events caused treatment discontinuation in two CRB-913 participants and one placebo participant.

Key Figures

Mean weight loss: 5% P-value vs. placebo: <0.0001 Study enrollment: 254 participants +3 more
Mean weight loss
5%
At 60 mg after 12 weeks
P-value vs. placebo
<0.0001
For each of the 20 mg, 40 mg, and 60 mg cohorts
Study enrollment
254 participants
CANYON-1 Phase 1b study
At least 5% weight loss
44.4%
Participants completing the study at 60 mg
Discontinuation due to adverse events
8.3%
Across all study cohorts
Serious or severe psychiatric adverse events
0 reported
CANYON-1 study

Previous Clinical trial Reports

1 past event · Latest: Sep 14
Same Type 1 event
  1. Sep 14

    CANYON-1 topline data

    24h Move
    -0.5%

    Earlier CANYON-1 topline reported 5% week-12 loss at 60 mg; poster adds detailed safety.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

placebo-controlled, glp-1, teae, mmrm
4 terms
placebo-controlled medical
"double-blind, placebo-controlled, dose-ranging study"
"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.
glp-1 medical
"in line with published GLP-1 data"
GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.
teae medical
"Any TEAE, n (%)"
A treatment-emergent adverse event (TEAE) is any new or worsening medical problem that appears after a patient begins a drug or other medical treatment. Investors monitor TEAEs because they reveal safety issues that can influence regulatory approval, product labeling, commercial use and legal risk—like finding unexpected side effects after launch that can shrink the market or require costly warnings or restrictions.
mmrm technical
"using a mixed model for repeated measures (MMRM)"
MMRM is a statistical method used in clinical trials to analyze repeated measurements from the same patients over time, accounting for natural differences between individuals and for missing visits without simply guessing missing values. Think of it like comparing students’ test-score trends across semesters while recognizing each student’s pattern rather than averaging everyone together; for investors, MMRM matters because it influences how robust and reliable reported treatment effects appear, which can affect regulatory interpretation and market reaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateauing observed
  • Corresponding significant reductions were also seen in waist circumference and body mass index (BMI)
  • Treatment-emergent psychiatric adverse events (AEs) were infrequent, mostly mild, and in line with published GLP-1 data
  • No serious or severe psychiatric AEs were reported, including no cases of severe or serious suicidality or depression
  • Vomiting, nausea, and constipation occurred at lower rates and were milder than those reported in published studies of oral GLP-1s

NORWOOD, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, announced today that additional data from the CANYON-1 Phase 1b obesity study were presented in a poster at ObesityWeek® 2026.

The data demonstrated statistically significant and clinically meaningful weight loss at all three doses of CRB-913, with the highest dose of 60 mg achieving a mean weight loss of 5% at 12 weeks. CRB-913 had a favorable safety and tolerability profile.  The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is line with published GLP-1 data. Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe treatment-emergent psychiatric AEs were reported. These data support CRB-913’s potential to establish a new class of oral, non-incretin obesity medicines.

“We’re pleased to share the CANYON-1 trial data at ObesityWeek®. While the rise of incretin-based therapies has been remarkable, a significant number of people either do not adequately respond to or cannot tolerate these therapies, with more than 60% discontinuing treatment within the first year on these medicines,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “In the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We’re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.”

Study Design

The CANYON-1 Phase 1b clinical trial was a 16-week, double-blind, placebo-controlled, dose-ranging study that enrolled 254 obese, non-diabetic adult participants at 15 investigational sites in the United States (NCT07310901). The trial included three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once daily, as well as a placebo cohort (randomization ratio of 1:1:1:1). A dose titration regimen was used, with all participants receiving CRB-913 starting at 20 mg/day and those assigned to the higher-dose cohorts titrating up every two weeks to either 40 mg/day or 60 mg/day, depending on their assigned cohort. Participants were dosed for 12 weeks and followed for an additional 4 weeks.

Efficacy

CRB-913 demonstrated rapid, statistically significant, and clinically meaningful weight loss at all dose levels, with no evidence of plateauing at any of the doses. Weight loss response rates were significantly higher across all three CRB-913 cohorts compared to the placebo cohort.

  CRB-913
CohortPlacebo
(n = 66)
20 mg
(n = 65)
40 mg
(n = 61)
60 mg
(n = 62)
LS mean weight loss from baseline at week 12, %10.0%2.8%3.3%5.0%
LS mean weight loss at week 12, % (placebo-adjusted)1NA2.8%3.3%5.0%
p-value vs. placeboNA<0.0001<0.0001<0.0001
Change in waist circumference from baseline, cm-0.84-3.03-3.04-3.94
p-value0.21<0.0001<0.0001<0.0001
BMI percent change from baseline-0.06-2.81-3.34-4.99
p-value0.89<0.0001<0.0001<0.0001

1 Efficacy estimand. The LS means and p-values were derived using a mixed model for repeated measures (MMRM), with percent change from baseline as the dependent variable; sex, treatment group, visit, and the treatment group-by-visit interaction as categorical fixed effects; and baseline weight as a covariate. An unstructured covariance matrix was used.

All participants who completed the study and received CRB-913 at the 60 mg dose lost weight, with 44.4% losing at least 5.0% from baseline. Similarly, 6.7% of the participants in that cohort lost more than 7.5% of their weight from baseline. The highest recorded weight loss for this cohort was 13.4% from baseline. Participants treated with CRB-913 also experienced dose-dependent reductions in waist circumference and body mass index during the study.

Safety

CRB-913 was safe and well tolerated. The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is in line with published GLP-1 data.

  CRB-913 
Safety measurePlacebo
(n = 66)
20 mg
(n = 65)
40 mg
(n = 61)
60 mg
(n = 62)
Total
(N = 254)
Any TEAE, n (%)28 (42.4)39 (60.0)45 (73.8)45 (72.6)157 (61.8)
Severe TEAE0 (0.0)3 (4.6)2 (3.3)1 (1.6)6 (2.4)
Severe psychiatric TEAE0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
Severe gastrointestinal TEAE0 (0.0)0 (0.0)0 (0.0)0 (0.0) 0 (0.0)
Serious TEAE0 (0.0)2 (3.1)1 (1.6)1 (1.6)4 (1.6)
Any TRAE, n (%)14 (21.2)27 (41.5)34 (55.7)33 (53.2)108 (42.5)
Severe TRAE0 (0.0)0 (0.0)1 (1.6)0 (0.0)1 (0.4)
Serious TRAE0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
Treatment discontinuation for any reason, n (%)12 (18.2)10 (15.4)16 (26.2)16 (25.8)54 (21.3)
Treatment discontinuation due to an AE, n (%)3 (4.5)2 (3.1)8 (13.1)8 (12.9)21 (8.3)


Psychiatric Adverse Events

Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe psychiatric AEs were reported.

  CRB-913
Adverse event, n (%)Placebo
(n = 66)
20 mg
(n = 65)
40 mg
(n = 61)
60 mg
(n = 62)
Suicidality0000
Depressive symptoms0001 (1.6%)
(moderate)
Anxiety3 (4.5%)2 (3.1%)5 (8.2%)3 (4.8%)


Fifty percent of the psychiatric AEs occurred within the first 28 days, a pattern similar to that seen with GLP-1 analogs. No cases of suicidal ideation or serious or severe depression were observed. Psychiatric AEs did not appear to be dose-related; rates of depression and anxiety were in line with those reported in published GLP-1 studies. Only one of the 188 participants receiving CRB-913 reported transient, moderate depressive symptoms, a rate that is in line with published GLP-1 data. A total of 15 participants (8%) on CRB-913 reported mild irritability that was transient, resolved spontaneously, and did not affect their daily function. All 15 participants experienced weight loss, and 12 participants had concomitant unrelated AEs.

Gastrointestinal Adverse Events

Treatment-emergent gastrointestinal AEs were all mild or moderate, with no serious or severe events.

  CRB-913
Adverse event, n (%)Placebo
(n = 66)
20 mg
(n = 65)
40 mg
(n = 61)
60 mg
(n = 62)
Vomiting03 (4.6%)5 (8.2%)1 (1.6%)
Nausea3 (4.5%)10 (15.4%)16 (26.2%)14 (22.6%)
Constipation2 (3.0%)3 (4.6%)1 (1.6%)3 (4.8%)
Diarrhea2 (3.0%)14 (21.5%)16 (26.2%)14 (22.6%)


Vomiting, nausea, and constipation occurred at lower rates and were less severe than those reported in published studies of oral GLP-1s. Treatment discontinuations due to gastrointestinal AEs occurred in only three participants (two on CRB-913 and one on placebo).

Next Steps

Corbus plans to engage with the FDA to discuss the data and the development plans for CRB-913. The Company is also evaluating the potential for CRB-913 in combination with GLP-1 therapies.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes SUTA-E (sutantatug envedotin), a next-generation antibody-drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered, highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn, and Facebook.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the potential benefits and development of CRB-913, future clinical studies and regulatory discussions, potential combination therapies, development timing and funding. They reflect current expectations and assumptions and are subject to risks and uncertainties that could cause actual outcomes to differ materially. These include the possibility that early clinical findings will not be reproduced in larger or longer studies; additional safety findings or changes following further analysis; delays in clinical or regulatory activities; and the availability and terms of financing or partnering arrangements. Further risks are described under the heading “Risk Factors” in Corbus most recent Annual Report on Form-10-K and subsequent Quarterly Reports on Form10-Q filed with the Securities and Exchange Commission. Forward-looking statements apply only as of the date of this release. Corbus does not undertake to update them except as required by law.

Investor Contacts

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

Media Contact

Liz Melone
Founder and Principal
Melone Communications, LLC
liz@melonecomm.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How was Corbus's CANYON-1 CRB-913 trial designed?

CANYON-1 was a 16-week, double-blind, placebo-controlled, dose-ranging study at 15 United States sites. Participants were randomized 1:1:1:1 to placebo or once-daily oral CRB-913 at 20 mg, 40 mg or 60 mg. Active treatment started at 20 mg/day, with higher-dose groups increasing every two weeks. Dosing lasted 12 weeks, followed by four weeks of follow-up.

Keep reading